NYSE
LLY
Last Price
US $1133.00
KEY FIGURES
MKT CAP
$1.1T
EPS
TTM
$28.26
PEG
TTM
0.31x
P/E
TTM
40.10x
P/S
TTM
16.37x
YIELD
0.57%
GROWTH
Revenue Y/Y
Profit margin
Current Ratio
Capital Returns
101.30%
Return on equity
ROIC: 32.06%
Valuation History
40.1X
Price to Earnings
EV/EBITDA: 33.0X
Cash flow
Profit margin
21.58%
(FY vs FY)
EBITDA Y/Y
25.67%
(FY vs FY)
Cash flow Y/Y
14.95%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $1133.00
-88.42%
Default assumptions
EBITDA Multiple
Fair Value
Market $1133.00
-85.03%
Default assumptions
EARNINGS FV (GRAHAM)
Fair Value
Market $1133.00
-56.31%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
Eli Lilly and Company cash flow to debt ratio of 39.56% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.
Financial stability - Healthy cash flow growth.
Eli Lilly and Company's free cash flow has increased 2.07K% from $414.30M last year to $8.97G, signaling increasing performance
Financial risk - Healthy debt to equity ratio.
Eli Lilly and Company's debt to equity ratio is 1.39, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negatve, the company spent its own equity and risk bancrupcy
Financial stability - Healthy debt to equity ratio development.
Eli Lilly and Company's debt has decreased relative to shareholder equity from 2.37 last year to 1.39 today, signaling strengthened financials
Financial stability - Net debt/EBITDA.
Eli Lilly and Company has a net debt to EBITDA ratio of 1.27x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
Eli Lilly and Company's interest coverage ratio of 37.50 indicates that earnings with good margin can cover interest payments on company debt
Financial stability - Profit margin growth.
Eli Lilly and Company's profit margin has increased (48.79%) in the last year from 23.51% to 34.98%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
Eli Lilly and Company's short-term assets of $55.63G exceed its short-term liabilities of $35.23G
Increasing perfomance - ROA.
Eli Lilly and Company's return on assets of 21.68% is higher than the 5.00% threshold, indicating efficient asset utilization
Increasing perfomance - Absolute return on equity.
Eli Lilly and Company's return on equity of 101.30%, is higher than 15.00%, indicating good performance
Decreasing perfomance - Earnings quality.
Eli Lilly and Company's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Increasing perfomance - Earnings stability.
Eli Lilly and Company had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings
Increasing perfomance - Free cash flow.
Eli Lilly and Company has positive free cash flow, indicating the company generates cash after capital expenditures
Decreasing perfomance - FCF yield.
Eli Lilly and Company has a free cash flow yield of 0.82%, which is below the 2.00% threshold, indicating limited cash return relative to market value
Increasing perfomance - Healthy earnings growth.
Eli Lilly and Company's yearly earnings has increased 94.88% since last year from $10.59G to $20.64G, signaling increasing performance
Increasing perfomance - Healthy revenue growth.
Eli Lilly and Company's yearly revenue has increased 44.70% since last year from $45.04G to $65.18G, signaling increasing performance
Increasing perfomance - ROIC.
ROIC 32.06% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.
Increasing perfomance - 3-year revenue CAGR.
Eli Lilly and Company's 3-year revenue CAGR of 31.69% is positive, indicating growing revenue over the past 3 years
Increasing perfomance - Revenue consistency.
Eli Lilly and Company had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance
Increasing perfomance - ROE consistency.
Eli Lilly and Company had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity
Overvalued - DCF valuation.
Eli Lilly and Company is overvalued relative to its fair value price of 131.15 based on Discounted Cash Flow model
Overvalued - Earnings yield.
Eli Lilly and Company has an earnings yield of 2.44%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings
Overvalued - EBITDA valuation.
Eli Lilly and Company is overvalued relative to its fair value price of 169.58 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Eli Lilly and Company has an EV/EBITDA ratio of 33.99x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings
Overvalued - Earnings Fair Value vs Stock Price.
Eli Lilly and Company is overvalued relative to its fair value price of 495.00 based on Earnings Fair Value model
Undervalued - PEG ratio value.
Eli Lilly and Company has a PEG-ratio under 1 which is considered undervalued
Overvalued - P/B ratio.
Eli Lilly and Company has a price-to-book ratio of 33.13x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value
Overvalued - P/S ratio.
Eli Lilly and Company has a price-to-sales ratio of 15.06x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue